StockNews.com Begins Coverage on Ekso Bionics (NASDAQ:EKSO)

Investment analysts at StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a note issued to investors on Tuesday. The firm set a “hold” rating on the stock.

Several other research firms have also recently issued reports on EKSO. HC Wainwright upped their price target on shares of Ekso Bionics from $9.25 to $10.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Lake Street Capital assumed coverage on shares of Ekso Bionics in a research report on Monday, June 24th. They issued a “buy” rating and a $2.50 price target on the stock.

Ekso Bionics Trading Down 0.9 %

EKSO opened at $1.05 on Tuesday. The firm has a market capitalization of $19.08 million, a P/E ratio of -1.08 and a beta of 1.51. The firm’s 50 day moving average is $1.15 and its 200-day moving average is $1.47. The company has a quick ratio of 2.11, a current ratio of 2.81 and a debt-to-equity ratio of 0.33. Ekso Bionics has a 52-week low of $0.62 and a 52-week high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings data on Monday, July 29th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The firm had revenue of $4.95 million during the quarter, compared to analyst estimates of $5.34 million. Ekso Bionics had a negative return on equity of 88.93% and a negative net margin of 68.41%. During the same quarter in the prior year, the firm earned ($0.31) EPS. Analysts expect that Ekso Bionics will post -0.43 EPS for the current fiscal year.

Hedge Funds Weigh In On Ekso Bionics

A hedge fund recently bought a new stake in Ekso Bionics stock. Kent Lake Capital LLC bought a new stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 141,158 shares of the company’s stock, valued at approximately $353,000. Kent Lake Capital LLC owned approximately 0.95% of Ekso Bionics at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.